Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Stivarga® (regorafinib) – New orphan indication
April 27, 2017 – The FDA announced the approval of Bayer’s Stivarga (regorafinib), for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar® (sorafenib).
